Several screening programs for cervical cancer have been successfully implemented in the clinical community, and are comprised of tests based on the appearance of abnormal cells in cytological specimens, and more recently, based on HPV type. There remains however, a great need for additional biomarkers that will increase the sensitivity with which precancerous and cancerous lesions are detected. Furthermore, there is a lack of testing available for the identification of atypical or moderately abnormal squamous cell lesions that will progress to higher grades.
The FISH-based HPV-Associated Cancer Test, FHACT®, is the only four color FISH Probe that can be used for cervical cancer screening as additional triage before referral for colposcopy. FHACT® can be used on leftover thin prep specimen (no resampling) and conventional Pap smears.
To learn more, please visit www.cgifhact.com.